Keybank National Association OH Takes $452,000 Position in Protagonist Therapeutics, Inc. $PTGX

Keybank National Association OH purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,286 shares of the company’s stock, valued at approximately $452,000.

Several other large investors have also made changes to their positions in the company. Farther Finance Advisors LLC lifted its stake in Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth $27,000. Osaic Holdings Inc. boosted its stake in Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after buying an additional 525 shares in the last quarter. Hantz Financial Services Inc. grew its position in Protagonist Therapeutics by 222.4% in the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock valued at $83,000 after acquiring an additional 656 shares during the last quarter. Finally, Canton Hathaway LLC bought a new position in Protagonist Therapeutics in the fourth quarter valued at about $87,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Down 1.7%

Shares of Protagonist Therapeutics stock opened at $137.64 on Friday. The stock has a market cap of $8.85 billion, a price-to-earnings ratio of -76.04 and a beta of 1.79. Protagonist Therapeutics, Inc. has a twelve month low of $50.49 and a twelve month high of $141.10. The company’s fifty day moving average is $109.46 and its 200 day moving average is $97.80.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The firm had revenue of $56.37 million for the quarter, compared to the consensus estimate of $11.70 million. As a group, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PTGX has been the topic of a number of research analyst reports. Wolfe Research began coverage on shares of Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price target on the stock. Citizens Jmp increased their price objective on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Jefferies Financial Group restated a “buy” rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Finally, Barclays upped their price target on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $116.93.

Insider Buying and Selling

In related news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the transaction, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at $52,410,617.36. The trade was a 12.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bryan Giraudo sold 36,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $100.14, for a total transaction of $3,605,040.00. Following the transaction, the director owned 27,825 shares of the company’s stock, valued at approximately $2,786,395.50. The trade was a 56.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 162,880 shares of company stock valued at $16,539,792 over the last three months. 5.19% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.